A post-mortem examination conducted through dr. Amy Rapkiewicz, director of the Department of Pathology at NYU Langone Medical Center, revealed clotting in the body’s small blood vessels.
Researchers from the National Institutes of Health have introduced a third trial to treat blood clots in patients with COVID-19.
About a year after the onset of the COVID-19 pandemic, fitness experts and scientists are still learning about the long- and short-term effects this new virus can have on other people who succeed over infection. Effects.
At the beginning of the pandemic, doctors discovered that many of their patients who had succumbed to the COVID-19 virus had blood clots in their bodies, “even in their smallest blood vessels,” according to NIH.
Having blood clots can cause other potentially fatal effects, such as “organ damage through a central attack, stroke, and pulmonary embolism,” according to a statement from NIH.
DOSSIER – A observes a blood clot expelled through a patient with COVID-19 at the General Hospital of Mexico City on May 30, 2020 in Mexico City, Mexico.
RELATED: Medical images the true extent of the long-term effects of COVID-19
Commercial
THE NIH has begun its third Phase 3 trial of the main antithrombotic protocol ACTIV-4 for adaptive trials, which is testing anticoagulant remedies that can potentially save you any potentially fatal blood clots in released adult patients, according to a NIH press release.
The trial is part of the COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, which is “a public-private component to expand a coordinated strategy to prioritize and drive the progression of maximum promising remedies and vaccines,” according to the NIH website.
The first patient was registered on February 15 and tests are underway at more than 100 sites around the world, according to the NIH.
RELATED: A study reveals that about a third of other people with “mild” COVID-19 still have symptoms months later
In this phase 3 trial, “Eliquis® (apixaban 2. 5 mg), an anticoagulant or anticoagulant, donated through Bristol Myers Squibb/ Pfizer, is being tested in hospital discharge patients following a severe diagnosis of COVID-19,” he said.
Researchers will compare patients within forty-five days of hospitalization to see if they “develop thrombotic complications: central attack, stroke, blood clots in the main veins and arteries, deep vein and pulmonary thrombosis, or death. “
This NIH essay, overseen by the National Heart, Lung and Blood Institute, works in collaboration with Duke University, Durham, North Carolina, the University of Pittsburgh; University of Illinois at Chicago; Brigham and Women’s Hospital, Boston; Wisconsin Medical College; University of California, San Francisco; and the University of Ottawa and the Ottawa Hospital Research Institute to conduct this trial.
RELATED: COVID-19 symptoms remained for at least 6 months for some Wuhan patients, finds
At the beginning of the pandemic, doctors and scientists from dozens of hospitals and universities around the world were looking for answers as they searched to measure the threat of viral clots and tested drugs to treat or save them.
“COVID-19 is the ultimate thrombotic (clot-producing) disease that has ever been noticed in our lives,” said Dr. Alex Spyropoulos, a clot specialist and professor at feinstein Institutes of Medical Research in Manhasset, New York.
Certain situations that make some COVID-19 patients vulnerable to serious complications, such as obesity and diabetes, would possibly increase the threat of clots, but many claim that the way the virus attacks and the body’s reaction play a role.
Coagulation has been observed in coronavirus infections, which adds SARS, but on a much smaller scale, Spyropoulos said.
RELATED: “Today is the 353rd”: Take 189 tablets a week almost a year after diagnosis of COVID-19 to combat symptoms
Some hospitals have found that 40% of deaths in COVID-19 patients were caused by blood clots, which Spyropoulos said in its formula of 23 New York-area hospitals, Northwell Health, which treated more than 11,000 patients with COVID-19 in May. 2020.
Scientists claim that coronavirus enters the framework through enzyme receptors throughout the frame, adding cells that line the inside of blood vessels. Some may promote clotting by injuring those vessels one way or another as it spreads. reaction when the body tries to fight the infection, causing inflammation that can also damage vessels and promote clotting, said Dr. Valentin Fuster, director of Mount Sinai Heart Hospital in New York.
The Associated Press contributed to the report.